Abstract
Hypoxia is a characteristic feature of many solid tumors which has been described in a wide range of tumor types. Its presence impairs the effectiveness of common anti-cancer therapies and accordingly, tumor hypoxia has been associated with an aggressive tumor phenotype, poor response to radio- and chemotherapy, and worse prognosis. In order to predict outcome and identify patients with a worse prognosis and/or patients that would benefit from appropriate treatments, in vivo measurement of tumor hypoxia is required. Given the difficulties associated with invasive methods, a non-invasive method is of major clinical interest. Although several candidate molecules have been labeled with PET and SPECT labels, none of them is used in daily clinical routine due to a number of difficulties that complicate their use. This review aims to give an overview of the most important hypoxia tracers, their prognostic significance and how these tracers can play a role in tomorrows personalized medicine.
Keywords: Hypoxia, PET, SPECT, nitroimidazole.
Current Pharmaceutical Design
Title:Radiolabelled Probes Targeting Tumor Hypoxia for Personalized Medicine
Volume: 20 Issue: 14
Author(s): Gilles Mees, Mike Sathekge, Alex Maes and Christophe Van de Wiele
Affiliation:
Keywords: Hypoxia, PET, SPECT, nitroimidazole.
Abstract: Hypoxia is a characteristic feature of many solid tumors which has been described in a wide range of tumor types. Its presence impairs the effectiveness of common anti-cancer therapies and accordingly, tumor hypoxia has been associated with an aggressive tumor phenotype, poor response to radio- and chemotherapy, and worse prognosis. In order to predict outcome and identify patients with a worse prognosis and/or patients that would benefit from appropriate treatments, in vivo measurement of tumor hypoxia is required. Given the difficulties associated with invasive methods, a non-invasive method is of major clinical interest. Although several candidate molecules have been labeled with PET and SPECT labels, none of them is used in daily clinical routine due to a number of difficulties that complicate their use. This review aims to give an overview of the most important hypoxia tracers, their prognostic significance and how these tracers can play a role in tomorrows personalized medicine.
Export Options
About this article
Cite this article as:
Mees Gilles, Sathekge Mike, Maes Alex and Wiele Van de Christophe, Radiolabelled Probes Targeting Tumor Hypoxia for Personalized Medicine, Current Pharmaceutical Design 2014; 20 (14) . https://dx.doi.org/10.2174/13816128113196660662
DOI https://dx.doi.org/10.2174/13816128113196660662 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Bisphenol A as a Factor in the Mosaic of Autoimmunity
Endocrine, Metabolic & Immune Disorders - Drug Targets EPO Relies upon Novel Signaling of Wnt1 that Requires Akt1, FoxO3a,GSK-3β, and β-Catenin to Foster Vascular Integrity during Experimental Diabetes
Current Neurovascular Research Bone Metastases Radiopharmaceuticals: An Overview
Current Radiopharmaceuticals Basic and Clinical Aspects of Gene Therapy for Retinopathy Induced by Diabetes
Current Gene Therapy Patent Annotations
Recent Patents on Anti-Cancer Drug Discovery Phycobilins and Phycobiliproteins Used in Food Industry and Medicine
Mini-Reviews in Medicinal Chemistry Energy Remodeling, Mitochondrial Disorder and Heart Failure
Current Pharmaceutical Design Before and After Preeclampsia: What Biomarkers are there?
Current Women`s Health Reviews Association of Viruses in the Development of Cardiovascular Diseases
Current Pharmaceutical Design Antiarrhythmic Therapy on Prevention of Postoperative Atrial Fibrillation in Patients After Heart Surgery
Current Medicinal Chemistry - Cardiovascular & Hematological Agents Bioactivity and Pharmacological Actions of Carbon Monoxide-Releasing Molecules
Current Pharmaceutical Design May Oxygen-Ozone Therapy Improves Cardiovascular Disorders?
Cardiovascular & Hematological Disorders-Drug Targets Targeting Antioxidants to Mitochondria: A Potential New Therapeutic Strategy for Cardiovascular Diseases
Current Pharmaceutical Design Neutrophil Gelatinase-Associated Lipocalin (NGAL) as a New Biomarker for Non – Acute Kidney Injury (AKI) Diseases
Inflammation & Allergy - Drug Targets (Discontinued) Outcome Prediction after Non-aneurysmal Non-traumatic Subarachnoid Hemorrhage
Current Neurovascular Research Semisynthetic Hybrid Biopolymers for Non-pharmacological Intervention of the Microcirculation
Current Drug Metabolism 12-Lipoxygenase: A Potential Target for Novel Anti-Platelet Therapeutics
Cardiovascular & Hematological Agents in Medicinal Chemistry Myocardial Expression of TNF-α, IL-1β, IL-6, IL-8, IL-10 and MCP-1 After a Single MDMA Dose Administered in a Rat Model
Current Pharmaceutical Biotechnology Microvasculature Recovery by Angiogenesis After Myocardial Infarction
Current Pharmaceutical Design GRK2 and Beta-Arrestins in Cardiovascular Disease: Established and Emerging Possibilities for Therapeutic Targeting
Current Molecular Pharmacology